Artificial Intelligence in Biopharma

Explore how cells house the nucleus, DNA, and genes, where genes encode proteins. Understand how mRNA copies recipes, ribosomes assemble amino acids into proteins that drive body functions.

Discover how dna stores biological instructions with a four-base alphabet, a, t, g, and c, and how gene activation directs protein production, including secreted proteins like insulin.

Proteins assemble from 20 amino acids, and their properties come from the exact order of these blocks. DNA uses three-letter codons to encode amino acids, including start and stop signals.

Manufacture biologic drugs like monoclonal antibodies using CHO cells in large bioreactors; cells secrete proteins for easy purification, and codon optimisation boosts yield and scalable manufacturing efficiency.

Identify the disease-related protein and design a molecule that binds it precisely, while AI accelerates discovery, increases thoroughness, and catches early problems to shorten the 10-15 year, $2 billion path.

Leverage AI-driven target identification to link diseases, genes, and proteins via knowledge graphs, enabling human genetic validation and rapid prioritization of therapeutic targets.

Generative AI models learn rules of chemistry and biology from millions of molecules to generate novel small-molecule drugs and monoclonal antibodies with high predicted affinity, despite the vast chemical space.

AlphaFold predicts protein structures from sequences, drawing on the PDB and crystallography and cryo-EM. It enables docking against these structures in binding pockets, unlocking previously undruggable drug targets.

Isomorphic Labs applies deep learning and AlphaFold 3 to extend protein structure prediction to drug design, predicting how drug candidates bind and designing molecules with optimized binding, safety, and manufacturability.

Explore how AI models predict ADMET properties from molecular structure, enabling early absorption, distribution, metabolism, excretion, and toxicity assessments, while multi-property optimization balances liver safety, HRG interference, and solubility.

AI accelerates lead optimization from hit to candidate using Bayesian optimization, retro synthesis, and deep learning QSAR. A closed-loop system automates design, synthesis, and testing across biopharma players.

Artificial intelligence transforms every stage of drug development, from target identification to design. Generative AI enables novel molecules, safety prediction, and closed-loop optimization, while AlphaFold expands reachable targets.

Use AI-driven synthetic control arms built from digital twins to simulate patient outcomes, enabling ethical, cost-effective trials. Optimize site selection and trial design with FDA-accepted in silico modeling.

Analyze trial data continuously with AI to detect anomalies in real time and trigger safety reviews, while automating adverse event coding from free text into standard terminology using wearable data.

Explore real-time process monitoring with AI-driven PAT, translating spectroscopic signals into quality attributes to enable RTRT and continuous manufacturing in biopharma.

Explore how AI enhances biopharma manufacturing with real-time process monitoring, bioprocess optimization, and AI-assisted batch review in CHO cell production, focusing on quality, risk, and validation challenges.

Explore how AI accelerates pharmacovigilance in biopharma, boosting adverse event processing, safety signal detection, and regulatory document authoring while ensuring validation, auditability, and explainability for patient safety and compliance.

Explore five AI success stories across drug discovery, clinical trials, manufacturing, and regulatory affairs, with concrete outcomes and measurable patient impact from discovery to bedside.

A knowledge graph driven AI identified barititinib, a rheumatoid arthritis drug, to block SARS-CoV-2 entry via clathrin-mediated endocytosis and knackenosis enzymes, reducing mortality in trials.

Discover how AI-driven target identification and generative molecule design enabled Rentocertib, a first-in-class TNIK inhibitor for IPF, delivering positive clinical signals and rapid development.

Leverage ai-powered clinical intelligence to tailor cancer treatment at the bedside by integrating pathology, genomics, imaging, and outcomes, and using immune profile scores to identify likely responders.